The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
